ArticleJournal of cellular and molecular medicine2025
Genetic and Multi-Omics Insights Into Monocyte Pantothenate-Mediated Protection in Acute Respiratory Distress Syndrome.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- RAW 264.7 macrophage cell line as a metabolomic model for analyzing and understanding inflammation processes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Genetic and Multi-Omics Insights Into Monocyte Pantothenate-Mediated Protection in Acute Respiratory Distress Syndrome.Journal of cellular and molecular medicine · 2025Article
- Ferroptosis in sepsis induced acute lung injury/acute respiratory distress syndrome (ALI/ARDS): a potential therapeutic strategy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) is a severe condition with complex pathogenesis, and emerging evidence highlights the potential role of metabolic factors, though the exact mechanisms are not fully understood. In this study, we used Mendelian randomisation (MR) and multi-omics approaches to investigate the causal relationship between plasma metabolites, immune cell profiles and ARDS risk. MR analysis of 1400 metabolites identified two causal metabolites linked to increased ARDS risk, primarily involved in pantothenate and CoA biosynthesis. Single-cell RNA sequencing of ARDS samples revealed that monocytes exhibited the highest levels of pantothenate synthesis. Intercellular communication and pseudotime analysis suggested that the pantothenate synthesis pathway influenced monocyte differentiation and interactions with other cell types. Gene set enrichment analysis showed that monocytes with high pantothenate synthesis were significantly enriched in phagocytosis-related pathways. Subsequent MR analysis demonstrated that CD33dim HLA DR+ CD11b+%CD33dim HLA DR+ were a risk factor against ARDS. Notably, monocytes with high pantothenate synthesis exhibited decreased expression of antigen presentation markers HLA-DRB5, HLA-DRB1 and HLA-DRA, suggesting that the high pantothenate synthesis monocytes exhibit attenuated antigen presentation and enhanced phagocytic function. Moreover, we developed a diagnostic model using machine learning algorithms. Shapley Additive explanation (SHAP) was leveraged to evaluate the model performance, with CALM2 identified as the most influential feature across the CatBoost and XGBoost models. In summary, this study integrates genetic, multi-omics and machine learning approaches to provide novel insights into the pathogenesis of ARDS and its potential therapeutic strategies targeting monocyte metabolism and function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.